Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-03-28 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
开源证券股份有限公司关于江苏德源药业股份有限公司2023年年度募集资金存放与实际使用情况的核查意见
Regulatory Filings
2024-03-28 Chinese
2023年年度独立董事述职报告（周伟澄）
Board/Management Information Classification · 95% confidence The document is titled as the "2023 Annual Independent Director's Work Report" of Jiangsu Deyuan Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance at board and committee meetings, opinions on various board resolutions, communication with auditors, and overall evaluation of their role during the year 2023. The content focuses on governance, director duties, and oversight activities rather than financial results or audit opinions alone. It is not an announcement or a brief notice but a substantive report on the independent director's work and opinions for the year. This fits best under the category of Board/Management Information (MANG), which includes announcements related to board members and their activities. The document is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) because it does not contain full financial statements or audit opinions but rather a director's detailed report on their duties and governance activities.
2024-03-28 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled '会计师事务所选聘制度' which translates to 'Accounting Firm Selection System'. It details the procedures, requirements, and governance related to the selection and appointment of the company's accounting firm. It includes sections on the responsibilities of the audit committee, evaluation criteria, procedures for appointment and replacement, and supervisory measures. There are no financial statements, audit opinions, or results of audits presented. The document is a governance policy or internal regulation related to audit firm selection rather than an audit report or annual report. It is not a report publication announcement since it is substantive and over 5,000 characters. It fits best under Governance Information (CGR) as it details internal rules and governance practices regarding auditor selection.
2024-03-28 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed statement from a securities company acting as a sponsor regarding the use of idle raised funds by Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes specifics about the raised funds, their usage, storage, and the company's plan to use some idle funds for cash management through low-risk financial products. It also details the decision-making process, approvals by the board and supervisory committee, and the sponsor's opinion. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or a certification. It is a regulatory disclosure about the use of raised funds and related approvals, fitting best under Regulatory Filings (RNS) as it does not constitute a full report but a compliance and disclosure document about fund usage and management.
2024-03-28 Chinese
2023年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a notice announcing the convening of the 2023 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed at the AGM such as the 2023 annual board report, supervisory board report, independent directors' reports, financial reports, profit distribution proposals, and other governance matters. It also includes procedural information about attendance, registration, and contact details. The document does not contain the actual annual report or financial statements but rather serves as an official announcement and invitation for shareholders to participate in the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2024-03-28 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors. It references regulatory rules about independent directors and evaluates their independence based on specific criteria. There is no financial data, no mention of annual or interim reports, no voting results, no management changes, and no other report types. This is a governance-related announcement about board members' independence, which fits best under Governance Information (CGR). The document length is short and focused solely on governance compliance and director independence.
2024-03-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.